Dr. Chaudhry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6001 North Mayfair
Spokane, WA 99208Phone+1 509-462-2273Fax+1 509-462-2275
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
- SUNY Upstate Medical UniversityResidency, Internal Medicine, 1993 - 1996
- Christian Medical College LudhianaClass of 1989
Certifications & Licensure
- ID State Medical License 2019 - 2026
- WA State Medical License 1999 - 2026
- IA State Medical License 1995 - 2000
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Join now to see all
Publications & Presentations
PubMed
- 32 citationsA Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal ...Daniel W. Bowles, Mark D. Kochenderfer, Allen Lee Cohn, Lucas Sideris, Nghia Nguyen
Clinical Colorectal Cancer. 2016-12-01 - 31 citationsZanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke
The Lancet. Haematology. 2023-01-01 - Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.Andrea Necchi, Rodryg Ramlau, Alejandro Falcón González, Arvind Chaudhry, Tilman Todenhöfer
JNCI Cancer Spectrum. 2024-04-30
Press Mentions
- American Oncology Network Physicians Research Presented at 64th ASH Annual Meeting & ExpositionDecember 14th, 2022
- Vial Announces Dr. Arvind Chaudhry of Summit Cancer Centers as a New Member of Vial’s Oncology CRO Advisory BoardJuly 27th, 2022
- American Oncology Network Physicians Research Presented at ASCO22June 13th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: